Celcuity announced that its Phase III Viktoria-1 clinical trial has successfully achieved the primary endpoint in the Pik3CA mutant patient cohort.
Experimental data show that this cohort of patients achieved a clinically significant improvement in progression-free survival.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Slide Insurance director Stephen L. Rohde disposes of 5,000 common shares for $109,450
JPMorgan Asset Management warns: AI concentration risk spreads to the bond market, investors need to beware of "crowded trades"
JPMorgan Asset Management has warned that the "AI factor" concentration risk has spread from equities to the fixed income sector, further highlighting the need for investors to remain cautious.
Korean exchanges launch KOSPI sidecar mechanism
10-Yr Benchmark Govt Yields - U.S. vs Other Nations
Crypto prices
More
